Senti Biosciences, Inc.

Senti Biosciences, Inc. (Nasdaq: SNTI) is a clinical-stage synthetic biology company focused on developing next-generation cell and gene therapies using proprietary gene circuit technology. The company went public through a de-SPAC merger with Dynamics Special Purpose Corp (DYNS), a blank-check vehicle that completed its IPO in 2021 and was sponsored by DYNS Sponsor, LLC. The business combination closed in June 2022, positioning Senti in the biotechnology and cell therapy sector alongside peers pursuing engineered cell medicines for oncology and other serious diseases. The May 2022 Form 10-Q filing covers operations during the period immediately preceding the close of that transaction. Visit SpacDesk and sign up for full data on SNTI, including filing history, deal timelines, and sponsor analytics.